Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRNX NASDAQ:PHVS NASDAQ:PRAX NASDAQ:PTGX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRNXCrinetics Pharmaceuticals$83.90+0.0%$45.66$25.83▼$84.00$8.85B0.232.25 million shs2.73 million shsPHVSPharvaris$34.45+2.7%$32.23$19.12▼$36.60$2.25B-2.34291,202 shs284,212 shsPRAXPraxis Precision Medicines$317.87+4.4%$310.80$37.19▼$366.52$8.86B2.74480,137 shs229,905 shsPTGXProtagonist Therapeutics$138.31+3.0%$114.12$50.49▼$143.29$8.64B1.79761,545 shs580,518 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRNXCrinetics Pharmaceuticals+0.01%+0.24%+133.82%+115.60%+169.59%PHVSPharvaris-3.98%-4.33%+2.29%+15.09%+44.30%PRAXPraxis Precision Medicines-3.17%-3.22%+7.84%-10.68%+465.33%PTGXProtagonist Therapeutics-4.71%+3.37%+18.97%+26.80%+142.02%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRNXCrinetics Pharmaceuticals$83.90+0.0%$45.66$25.83▼$84.00$8.85B0.232.25 million shs2.73 million shsPHVSPharvaris$34.45+2.7%$32.23$19.12▼$36.60$2.25B-2.34291,202 shs284,212 shsPRAXPraxis Precision Medicines$317.87+4.4%$310.80$37.19▼$366.52$8.86B2.74480,137 shs229,905 shsPTGXProtagonist Therapeutics$138.31+3.0%$114.12$50.49▼$143.29$8.64B1.79761,545 shs580,518 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRNXCrinetics Pharmaceuticals+0.01%+0.24%+133.82%+115.60%+169.59%PHVSPharvaris-3.98%-4.33%+2.29%+15.09%+44.30%PRAXPraxis Precision Medicines-3.17%-3.22%+7.84%-10.68%+465.33%PTGXProtagonist Therapeutics-4.71%+3.37%+18.97%+26.80%+142.02%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRNXCrinetics Pharmaceuticals 2.29Hold$78.27-6.71% DownsidePHVSPharvaris 2.79Moderate Buy$50.0845.38% UpsidePRAXPraxis Precision Medicines 2.95Moderate Buy$563.5077.27% UpsidePTGXProtagonist Therapeutics 2.94Moderate Buy$123.00-11.07% DownsideCurrent Analyst Ratings BreakdownLatest PHVS, PTGX, PRAX, and CRNX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2026CRNXCrinetics Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/17/2026PHVSPharvaris Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/17/2026PTGXProtagonist Therapeutics Johnson RiceSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$165.007/17/2026PTGXProtagonist Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform7/15/2026PHVSPharvaris Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$55.007/15/2026PHVSPharvaris Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy7/14/2026PTGXProtagonist Therapeutics BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$119.00 ➝ $151.007/13/2026PRAXPraxis Precision Medicines Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight7/13/2026PRAXPraxis Precision Medicines The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$447.007/13/2026PRAXPraxis Precision Medicines The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$447.007/8/2026CRNXCrinetics Pharmaceuticals TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold(Data available from 7/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRNXCrinetics Pharmaceuticals$7.70M1,148.89N/AN/A$9.71 per share8.64PHVSPharvarisN/AN/AN/AN/A$4.71 per shareN/APRAXPraxis Precision Medicines$8.55M1,036.52N/AN/A$34.85 per share9.12PTGXProtagonist Therapeutics$74.06M120.10N/AN/A$9.83 per share14.07Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRNXCrinetics Pharmaceuticals-$465.32M-$5.13N/AN/AN/A-2,747.18%-43.96%-39.61%8/4/2026 (Estimated)PHVSPharvaris-$198.79M-$3.18N/AN/AN/AN/A-67.56%-61.13%8/11/2026 (Estimated)PRAXPraxis Precision Medicines-$303.27M-$13.37N/AN/AN/AN/A-43.02%-40.22%8/3/2026 (Estimated)PTGXProtagonist Therapeutics-$130.15M-$1.81N/AN/AN/A-154.88%-17.76%-16.47%8/5/2026 (Estimated)Latest PHVS, PTGX, PRAX, and CRNX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2026Q2 2026PHVSPharvaris-$0.74N/AN/AN/AN/AN/A8/5/2026Q2 2026PTGXProtagonist Therapeutics$2.11N/AN/AN/A$190.99 millionN/A8/4/2026Q2 2026CRNXCrinetics Pharmaceuticals-$1.23N/AN/AN/A$14.84 millionN/A8/3/2026Q2 2026PRAXPraxis Precision Medicines-$3.6684N/AN/AN/A$1.25 millionN/A5/12/2026Q1 2026PHVSPharvaris-$0.8219-$0.70+$0.1219-$0.69N/AN/A5/7/2026Q1 2026CRNXCrinetics Pharmaceuticals-$1.22-$1.23-$0.01-$1.23$8.51 million$10.73 million5/7/2026Q1 2026PRAXPraxis Precision Medicines-$3.58-$3.20+$0.38-$3.20$0.10 millionN/A5/5/2026Q1 2026PTGXProtagonist Therapeutics-$0.5004$0.05+$0.5504$0.05$11.70 million$56.37 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCRNXCrinetics PharmaceuticalsN/AN/AN/AN/AN/APHVSPharvarisN/AN/AN/AN/AN/APRAXPraxis Precision MedicinesN/AN/AN/AN/AN/APTGXProtagonist TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRNXCrinetics PharmaceuticalsN/A18.6018.56PHVSPharvarisN/A11.2411.24PRAXPraxis Precision MedicinesN/A15.8815.88PTGXProtagonist TherapeuticsN/A17.7617.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRNXCrinetics Pharmaceuticals98.51%PHVSPharvarisN/APRAXPraxis Precision Medicines67.84%PTGXProtagonist Therapeutics98.63%Insider OwnershipCompanyInsider OwnershipCRNXCrinetics Pharmaceuticals3.80%PHVSPharvarisN/APRAXPraxis Precision Medicines3.00%PTGXProtagonist Therapeutics5.19%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRNXCrinetics Pharmaceuticals210105.44 million101.43 millionOptionablePHVSPharvaris3065.41 millionN/ANot OptionablePRAXPraxis Precision Medicines11027.88 million27.04 millionOptionablePTGXProtagonist Therapeutics12064.31 million60.97 millionOptionablePHVS, PTGX, PRAX, and CRNX HeadlinesRecent News About These CompaniesProtagonist Therapeutics (NASDAQ:PTGX) Sets New 52-Week High - Here's What HappenedJuly 20 at 9:59 AM | marketbeat.comSEB Asset Management AB Purchases New Shares in Protagonist Therapeutics, Inc. $PTGXJuly 20 at 5:28 AM | marketbeat.comJennison Associates LLC Purchases 740,847 Shares of Protagonist Therapeutics, Inc. $PTGXJuly 20 at 5:11 AM | marketbeat.comPrincipal Financial Group Inc. Raises Holdings in Protagonist Therapeutics, Inc. $PTGXJuly 19 at 4:47 AM | marketbeat.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Consensus Rating of "Moderate Buy" by BrokeragesJuly 19 at 2:13 AM | marketbeat.comBleakley Financial Group LLC Acquires Shares of 12,802 Protagonist Therapeutics, Inc. $PTGXJuly 18 at 3:37 AM | marketbeat.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: TG Therapeutics (TGTX), Protagonist Therapeutics (PTGX) and PROCEPT BioRobotics (PRCT)July 17, 2026 | theglobeandmail.comProtagonist Therapeutics Reports Granting of Inducement AwardsJuly 16, 2026 | accessnewswire.comA23,473 Shares in Protagonist Therapeutics, Inc. $PTGX Acquired by Calamos Advisors LLCJuly 16, 2026 | marketbeat.comBest Momentum Stocks to Buy for July 13thJuly 13, 2026 | zacks.comNew Strong Buy Stocks for July 13thJuly 13, 2026 | zacks.comProtagonist Therapeutics (NASDAQ:PTGX) Raised to Strong-Buy at Zacks ResearchJuly 10, 2026 | marketbeat.comProtagonist Therapeutics (PTGX) Stock Still Looks Stretched After FDA Priority ReviewJuly 9, 2026 | finance.yahoo.comProtagonist Therapeutics (PTGX) After Icotyde Launch And Rusfertide Review Looks UndervaluedJuly 9, 2026 | finance.yahoo.comNew Strong Buy Stocks for July 9thJuly 9, 2026 | zacks.comProtagonist Therapeutics (PTGX) Is Up 12.5% After Rusfertide Priority Review Focus - Has The Bull Case Changed?July 8, 2026 | finance.yahoo.comProtagonist Therapeutics (PTGX) Surges 7.1%: Is This an Indication of Further Gains?July 8, 2026 | zacks.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Johnson & Johnson (JNJ) and Protagonist Therapeutics (PTGX)July 8, 2026 | theglobeandmail.comWhy Protagonist Therapeutics, Inc.’s (PTGX) Stock Is Up 5.03%July 7, 2026 | aaii.comAPTGX Stock Surges 64% in Six Months: What Is Driving the Rally?July 7, 2026 | zacks.comProtagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $145.00 at Truist FinancialJuly 7, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePHVS, PTGX, PRAX, and CRNX Company DescriptionsCrinetics Pharmaceuticals NASDAQ:CRNX$83.90 +0.03 (+0.04%) Closing price 04:00 PM EasternExtended Trading$83.59 -0.31 (-0.37%) As of 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.Pharvaris NASDAQ:PHVS$34.45 +0.90 (+2.68%) Closing price 04:00 PM EasternExtended Trading$34.44 -0.01 (-0.01%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.Praxis Precision Medicines NASDAQ:PRAX$317.87 +13.44 (+4.41%) Closing price 04:00 PM EasternExtended Trading$317.98 +0.11 (+0.03%) As of 06:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.Protagonist Therapeutics NASDAQ:PTGX$138.31 +4.04 (+3.01%) Closing price 04:00 PM EasternExtended Trading$138.47 +0.16 (+0.12%) As of 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3M's Redemption Arc: Can Q2 Earnings Change the Narrative? Alphabet Is Planning a New AI Chip. Here's Why It Matters Ahead of Earnings 3 Photonics Companies Making Quantum Tech Possible Confidence Is Back, But Earnings Show the Consumer Is Being Picky Industrial and Utility Giants Boost Dividends as Data Center Tailwinds Build IREN’s $2.8 Billion AI Contract Haul Changes the Stock’s Story AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off 2 ETFs to Access the World's Best-Performing Stock Markets In 2026 Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
